1.Drug hypersensitivity reactions in Asia: regional issues and challenges
Bernard Yu Hor THONG ; Michaela LUCAS ; Hye Ryun KANG ; Yoon Seok CHANG ; Philip Hei LI ; Min Moon TANG ; James YUN ; Jie Shen FOK ; Byung Keun KIM ; Mizuho NAGAO ; Iris RENGGANIS ; Yi Giien TSAI ; Wen Hung CHUNG ; Masao YAMAGUCHI ; Ticha RERKPATTANAPIPAT ; Wasu KAMCHAISATIAN ; Ting Fan LEUNG ; Ho Joo YOON ; Luo ZHANG ; Amir Hamzah Abdul LATIFF ; Takao FUJISAWA ; Francis THIEN ; Mariana C CASTELLS ; Pascal DEMOLY ; Jiu Yao WANG ; Ruby PAWANKAR
Asia Pacific Allergy 2020;10(1):8-
There are geographical, regional, and ethnic differences in the phenotypes and endotypes of patients with drug hypersensitivity reactions (DHRs) in different parts of the world. In Asia, aspects of drug hypersensitivity of regional importance include IgE-mediated allergies and T-cell-mediated reactions, including severe cutaneous adverse reactions (SCARs), to beta-lactam antibiotics, antituberculous drugs, nonsteroidal anti-inflammatory drugs (NSAIDs) and radiocontrast agents. Delabeling of low-risk penicillin allergy using direct oral provocation tests without skin tests have been found to be useful where the drug plausibility of the index reaction is low. Genetic risk associations of relevance to Asia include human leucocyte antigen (HLA)-B*1502 with carbamazepine SCAR, and HLA-B*5801 with allopurinol SCAR in some Asian ethnic groups. There remains a lack of safe and accurate diagnostic tests for antituberculous drug allergy, other than relatively high-risk desensitization regimes to first-line antituberculous therapy. NSAID hypersensitivity is common among both adults and children in Asia, with regional differences in phenotype especially among adults. Low dose aspirin desensitization is an important therapeutic modality in individuals with cross-reactive NSAID hypersensitivity and coronary artery disease following percutaneous coronary intervention. Skin testing allows patients with radiocontrast media hypersensitivity to confirm the suspected agent and test for alternatives, especially when contrasted scans are needed for future monitoring of disease relapse or progression, especially cancers.
Adult
;
Allopurinol
;
Anaphylaxis
;
Anti-Bacterial Agents
;
Asia
;
Asian Continental Ancestry Group
;
Aspirin
;
Asthma
;
Carbamazepine
;
Child
;
Cicatrix
;
Contrast Media
;
Coronary Artery Disease
;
Diagnostic Tests, Routine
;
Drug Hypersensitivity
;
Ethnic Groups
;
Humans
;
Hypersensitivity
;
Penicillins
;
Percutaneous Coronary Intervention
;
Phenotype
;
Recurrence
;
Skin Tests
2.Comparison of clinical severity between single- and coinfections of respiratory syncytial virus and influenza virus with common respiratory viruses
Jin Sung PARK ; Shou Yu CHU ; Yi Yeon SHIN ; In Kyung RYU ; Chih Lung TANG ; Jungi CHOI ; Hyo Bin KIM ; Chang Keun KIM
Allergy, Asthma & Respiratory Disease 2019;7(2):86-91
PURPOSE: Multiple virus infections may affect clinical severity. We investigated the effect of coinfection of respiratory syncytial virus (RSV) and influenza virus with other respiratory viruses on clinical severity. METHODS: Data from 634 samples of a single tertiary hospital between September 2014 and April 2015 were analyzed for clinical characteristics (fever duration and O2 need, steroid use, and ICU care) between single infection and coinfection of RSV (n=290) and influenza virus (n=74) with 16 common respiratory viruses from hospitalized children. RESULTS: The RSV coinfection group (n=109) (3.1±2.7 days) showed significantly longer fever duration than the RSV single infection group (n=181) (2.6±2.6 days) (P=0.04), while there was no difference in O2 need, steroid use or ICU care in the 2 groups. The influenza coinfection group (n=38) showed significantly higher O2 need than the influenza single infection group (n=36) (21.1% vs. 5.6%, P=0.05), while there was no difference in fever duration between the 2 groups. CONCLUSION: The results indicate that RSV and Influenza coinfections can increase clinical severity and that the severity may be influenced by the nature of coinfecting viruses.
Child
;
Child, Hospitalized
;
Coinfection
;
Dyspnea
;
Fever
;
Humans
;
Influenza, Human
;
Orthomyxoviridae
;
Respiratory Syncytial Viruses
;
Tertiary Care Centers
3.Folic Acid in Stroke Prevention in Countries without Mandatory Folic Acid Food Fortification: A Meta-Analysis of Randomized Controlled Trials
Chia Yu HSU ; Shao Wen CHIU ; Keun Sik HONG ; Jeffrey L SAVER ; Yi Ling WU ; Jiann Der LEE ; Meng LEE ; Bruce OVBIAGELE
Journal of Stroke 2018;20(1):99-109
BACKGROUND AND PURPOSE: Additional folic acid (FA) treatment appears to have a neutral effect on reducing vascular risk in countries that mandate FA fortification of food (e.g., USA and Canada). However, it is uncertain whether FA therapy reduces stroke risk in countries without FA food fortification. The purpose of this study was to comprehensively evaluate the efficacy of FA therapy on stroke prevention in countries without FA food fortification. METHODS: PubMed, EMBASE, and clinicaltrials.gov from January 1966 to August 2016 were searched to identify relevant studies. Relative risk (RR) with 95% confidence interval (CI) was used as a measure of the association between FA supplementation and risk of stroke, after pooling data across trials in a random-effects model. RESULTS: The search identified 13 randomized controlled trials (RCTs) involving treatment with FA that had enrolled 65,812 participants, all of which stroke was reported as an outcome measure. After all 13 RCTs were pooled, FA therapy versus control was associated with a lower risk of any future stroke (RR, 0.85; 95% CI, 0.77 to 0.95). FA alone or combination of FA and minimal cyanocobalamin (≤0.05 mg/day) was associated with a lower risk of future stroke (RR, 0.75; 95% CI, 0.66 to 0.86) whereas combination of FA and cyanocobalamin (≥0.4 mg/day) was not associated with a lower risk of future stroke (RR, 0.95; 95% CI, 0.86 to 1.05). CONCLUSIONS: FA supplement reduced stroke in countries without mandatory FA food fortification. The benefit was found mostly in patients receiving FA alone or combination of FA and minimal cyanocobalamin.
Folic Acid
;
Food, Fortified
;
Humans
;
Outcome Assessment (Health Care)
;
Stroke
;
Vitamin B 12
4.Treatment of Intertrochanteric Fractures Using the Compression Hip Nail.
Je Min YI ; Kye Young HAN ; Keun Woo KIM ; Chang Hyun RYU
Hip & Pelvis 2014;26(3):166-172
PURPOSE: To investigate the clinical and radiologic outcomes following treatment of intertrochanteric fractures using the Compression Hip Nail(R) (CHN), which has a sliding lag screw. MATERIALS AND METHODS: Twenty-eight cases of intertrochanteric fractures treated with CHN from November 2012 to October 2013 and followed-up for >6 months were included. The patient population consisted of 11 men and 17 women with a mean age of 75.2 years at the time of surgery. For the initial 11 cases, 10 mm sliding lag screws were used; the remaining 17 cases used 20 mm sliding lag screws. Clinical variables including operation time, amount of transfusion, weight-bearing start time, postoperative physical activity, and complications were investigated. The average sliding of lag screws and the average union were investigated radiologically at 3 and 6 months after surgery. RESULTS: In an analysis of 23 cases (exclusion of 3 cases of lag screw cutout and 2 cases of nonunion), 11 (48%) recovered their pre-injury activity level. In an analysis of 25 cases (exclusion of 3 cases of cutout), 17 (68%) and 23 (92%) showed radiological union at postoperative months 3 and 6, respectively. Seven complications were noted. Cutout of the lag screw and the lateral protrusion of barrels were significantly greater in the group with 10 mm sliding lag screws as compared to the group using 20 mm sliding lag screws. CONCLUSION: The use of CHN for the treatment of intertrochanteric fracture yielded poor results. However, results from patients in the 20 mm sliding lag screw group were better than for the 10 mm sliding lag screw group. Therefore, use of the 20 mm sliding lag screw is advisable.
Female
;
Femur
;
Hip Fractures*
;
Hip*
;
Humans
;
Male
;
Motor Activity
;
Weight-Bearing
5.Pseudo Continuous Arterial Spin Labeling MR Imaging of Status Epilepticus.
Minkyung YI ; Seung Hong CHOI ; Keun Hwa JUNG ; Tae Jin YOON ; Ji Hoon KIM ; Chul Ho SOHN ; Kee Hyun CHANG
Journal of the Korean Society of Magnetic Resonance in Medicine 2012;16(2):142-151
PURPOSE: The purpose of this study was to describe arterial spin labeling MR image findings of status epilepticus. MATERIALS AND METHODS: A retrospective chart review within our institute revealed six patients who had been clinically diagnosed as status epilepticus and had also undergone MR imaging that included ASL in addition to routine sequences. RESULTS: Six patients with status epilepticus were studied by conventional MR and arterial spin labeling imaging. All patients showed increased regional CBF correlating with EEG pathology. Notably, in two patients, conventional MRI and DWI showed no abnormal findings whereas pCASL demonstrated regional increased CBF in both patients. CONCLUSION: Arterial spin labeling might offer additional diagnostic capabilities in the evaluation of patients with status epilepticus.
Electroencephalography
;
Humans
;
Retrospective Studies
;
Status Epilepticus
6.Primary Retroperitoneal Mucinous Cystadenoma.
Jung Im YI ; Hang Joo CHO ; Ok Ran SHIN ; Kee Hawn KIM ; Chang Hycok AHN ; Jeong Soo KIM ; Seung Jin YOO ; Keun Woo LIM ; Ji Il KIM
Journal of the Korean Surgical Society 2008;75(5):343-346
Primary retroperitoneal mucinous cystadenomas are rare tumors that are almost always found in women. They are similar to ovarian originated mucinous cystadenoma, but there is no any other evidence of an ovarian origin for primary retroperitoneal mucinous cystadenomas. A 33-year-old woman with complaints of RLQ pain was found to have a cystic mass in the right retroperitoneal space on her abdominal CT scan. The histological diagnosis was confirmed as primary mucinous cystadenoma. We report here on a case of retroperitoneal mucinous cystadenoma, and we also talk about this tumor, including its histogenesis, through a review of the available literature.
Adult
;
Cystadenoma, Mucinous
;
Female
;
Humans
;
Mucins
;
Retroperitoneal Space
7.The anti-tumor mechanisms of p53 through the regulation of expression and glycosylation of insulin-like growth factor binding protein-3.
Sun Young KIM ; Se Rim KIM ; Jung Chang LEE ; Ho Keun YI ; Dae Yeol LEE ; Pyoung Han HWANG
Korean Journal of Pediatrics 2006;49(4):431-438
PURPOSE: Insulin-like growth factor binding protein(IGFBP)-3 has been known as a tumor suppressor gene, and its anti-tumor function was divided into insulin-like growth factor(IGF)-dependent and IGF-independent mechanism. In IGF-independent mechanism, IGFBP-3 directly interacts with a cell without binding of IGFs, becoming an interesting object in oncology. Several studies demonstrate that one of the well-known tumor suppressor genes, p53, induces directly IGFBP-3 transcription, and the increment of IGFBP-3 expression induces apoptosis of many cancer cells. Recently, the anti-tumor mechanisms of IGFBP-3 have been reported, but post-translational modification of IGFBP-3 and its anti-tumor mechanism are not well known. In this study, we examined whether p53 regulated the glycosylation of IGFBP-3, and analysed the meaning of IGFBP-3 glycosylation related to the apoptosis of cancer cell. METHODS: The p53-mutated status of MDA-MB-231 human breast cancer cells was used in this experiment. The expression and glycosylation of IGFBP-3 were tested by Western blot analysis after infection of adenovirus mediated Ad/p53 and/or Ad/IGFBP-3. RESULTS: Ad/p53 infected cells resulted in growth retardation and the induced apoptosis. p53 induced direct expression and glycosylation of IGFBP-3. The increase of glcosylated IGFBP-3 was able to promote cellular apoptosis, and the glycosylation of IGFBP-3 was more activated by the double treatment of Ad/p53 and Ad/IGFBP-3. CONCLUSION: From this study, the anti-tumor activity of IGFBP-3 was shown to improve the stabilization of IGFBP-3 through the increment of glycosylation of IGFBP-3 by p53. This result suggests that the combined gene therapy of p53 and IGFBP-3 may appropriate treatment of cancer.
Adenoviridae
;
Apoptosis
;
Blotting, Western
;
Breast Neoplasms
;
Genes, Tumor Suppressor
;
Genetic Therapy
;
Glycosylation*
;
Humans
;
Insulin-Like Growth Factor Binding Protein 3
;
Protein Processing, Post-Translational
8.A Case of Hypersensitivity Syndrome to Both Vancomycin and Teicoplanin.
Hyouk Soo KWON ; Yoon Seok CHANG ; Yi Yeong JEONG ; Sang Min LEE ; Woo Jung SONG ; Hong Bin KIM ; Yoon Keun KIM ; Sang Heon CHO ; You Young KIM ; Kyung Up MIN
Journal of Korean Medical Science 2006;21(6):1108-1110
Drug hypersensitivity syndrome to both vancomycin and teicoplanin has not been previously reported. We describe here a 50-yr-old male patient with vertebral osteomyelitis and epidural abscess who developed hypersensitivity syndrome to both vancomycin and teicoplanin. Skin rash, fever, eosinophilia, interstitial pneumonitis, and interstitial nephritis developed following the administration of each drug, and resolved after withdrawing the drugs and treating with high dose corticosteroids. The vertebral osteomyelitis was successfully treated with 6-week course of linezolid without further complications. Skin patch tests for vancomycin and teicoplanin was done 2 months after the recovery; a weak positive result for vancomycin (10% aq.,+at D2 and +at D4 with erythema and vesicles; ICDRG scale), and a doubtful result for teicoplanin (4% aq.-at D2 and+/-at D4 with macular erythema; ICDRG scale). We present this case to alert clinicians to the hypersensitivity syndrome that can result from vancomycin and teicoplanin, with possible cross-reactivity, which could potentially be life-threatening.
Vancomycin/*adverse effects
;
Teicoplanin/*adverse effects
;
Syndrome
;
Middle Aged
;
Male
;
Humans
;
Drug Hypersensitivity/*diagnosis/*etiology
;
Drug Combinations
9.The Feasibility Test of Korean Medication Algorithm for the Treatment with Schizophrenic Patients(II): The Problem for Applying Algorithm to the Real Clinical Situation and Opinion of Revision.
Yong Min AHN ; Jun Soo KWON ; Won Myong BAHK ; Chul Eung KIM ; Jong Ik PARK ; Sang Yeol LEE ; Jung Seo YI ; Chang Hwa LEE ; Hong Seok JANG ; Duk In JON ; Sang Keun CHUNG ; In Won CHUNG ; Hyun Sang CHO ; Yeon Ho JOO ; Yong Seoung CHOI ; Yong Sik KIM ; Hong Shick LEE
Korean Journal of Psychopharmacology 2006;17(1):35-49
OBJECTIVES: The Korean College of Neuropsychopharmacology and the Korean Academy of Schizophrenia developed the Korean medication algorithm project for schizophrenia (KMAP) to aid clinical decisions. The purpose of this study was to investigate problems and revision of Korean Medication Algorithm for Schizophrenia after feasibility test. METHODS: A total of 108 schizophrenia patients were enrolled at 19 centers and treated according to the algorithm. Prescribing investigators were able to change the recommended treatment strategies of the algorithm if necessary. All subjects were assessed over a 4-month period. Appropriateness of choice, dosage, duration and switch of antipsychotics and definition of treatment response were examined. RESULTS: Compliance of 1(st) choice antipsychotics in KMAP was favorable. Atypical antipsychotics which is a 1(st) stage drug selected first was above 84%, especially in case of no previous medical history was nearly all. In case that shift of stage was needed, there is a trend that combination treatment stage (6(th) stage) and clozapine treatment stage (5(th) stage) were preferred to rather than 3(rd) stage and 4(th) stage (typical antipsychotics and atypical antipsychotics treatment stage). The rates of switching antipsychotics at the time points other than CDP (critical decision points) was low and the reason was almost the side effects. So the compliance of CDPs in KMAP was good in case of insufficiency of treatment response. Also the reasons why many investigators continued using current antipsychotics without switching despite insufficiency of treatment response were definition of treatment response, discrepancy between brief symptom rating scale for negative symptom and decision of clinicians. In addition, compliance of co-existence symptoms and side effect of medication in KMAP was favorable. CONCLUSION: It is some difference from clinical practice such as stage of antipsychotics, definition of treatment response and usefulness of brief symptom rating scale for negative symptom. But the majority apart from points of preceding paragraph is feasible in clinical practice. These results are essential to revise the next version of KMAP.
Antipsychotic Agents
;
Clozapine
;
Compliance
;
Cytidine Diphosphate
;
Humans
;
Research Personnel
;
Schizophrenia
10.PTEN/MMAC1 enhances the growth inhibition by anticancer drugs with downregulation of IGF-II expression in gastric cancer cells.
Pyoung Han HWANG ; Sun Young KIM ; Jung Chang LEE ; Sun Jun KIM ; Ho Keun YI ; Dae Yeol LEE
Experimental & Molecular Medicine 2005;37(5):391-398
PTEN/MMAC1 is a tumor suppressor gene that is mutated in a variety of advanced and metastatic cancers. Its major function is likely to be the phosphatase activity that regulates the phosphotidylinositol (PI)3-kinase/ Akt pathway. On the other hand, IGF system plays an important role in cell proliferation and cell survival via PI3-kinase/Akt and mitogen-activated protein kinase pathways in many cancer cells. To evaluate effect of PTEN on cell growth and IGF system in gastric cancer, human gastric adenocarcinoma cells (SNU-5 & -216) were transfected with human PTEN cDNA. Those PTEN- transfected gastric cancer cells had a lower proliferation rate than the pcDNA3-transfected cells. PTEN overexpression induced a profound decrease in the IGF-II and IGF-IR expression levels, and downregulation of IGF-II expression by PTEN was mediated through the regulation of the IGF-II promoter. In addition, a PI3-kinase inhibitor, LY294002, induced the downregulation of IGF-II expression. The PTEN-overexpressing SUN-5 and -216 cells were more sensitive to death induced by etoposide and adriamycin that induce DNA damage than the pcDNA3-transfected cells. These findings suggest that PTEN suppresses the cell growth through modulation of IGF system and sensitizing cancer cells to cell death by anticancer drugs.
Antineoplastic Agents/*pharmacology
;
Cell Line, Tumor
;
Cell Proliferation/drug effects
;
*Down-Regulation
;
Humans
;
Insulin-Like Growth Factor II/*genetics/*metabolism
;
PTEN Phosphohydrolase/genetics/*metabolism
;
Receptor, IGF Type 1/genetics/metabolism
;
Research Support, Non-U.S. Gov't
;
Stomach Neoplasms/*genetics/metabolism/*pathology

Result Analysis
Print
Save
E-mail